DigestRedComo funciona
Digest/ Comunicado

Compatibilidad
Ahorrar()
Compartir
Detalles de contacto
¿Quieres ver los próximos lanzamientos de este profesional en tu resumen?

Comunicados relacionados

07/02/2026
Farmacéutica
Anuncios breves
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
0
01/03/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
0
10/11/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Industria
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
Fuente
Genentech
Editor
Business Wire
0